Abstracts tagged "C-reactive protein (CRP)"

Abstract Number: 0408 • ACR Convergence 2022
Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non‑Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Philip C. Robinson¹, Walter P Maksymowych², Lianne Gensler³, Martin Rudwaleit⁴, Bengt Hoepken⁵, Lars Bauer⁵, Thomas Kumke⁵, Mindy Kim⁶ and Atul Deodhar⁷, ¹University of Queensland School of Clinical Medicine, Brisbane, Australia, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Smyrna, GA, ⁷Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Certolizumab pegol (CZP) has demonstrated clinical efficacy in patients (pts) with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (OSI) during the…
Abstract Number: 0414 • ACR Convergence 2022
Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis
Xenofon Baraliakos¹, Fabiana Ganz², Hideto Kameda³, Jessica Walsh⁴, Manish Jain⁵, Kristin D’Silva⁶, Peter Wung⁶, Xianwei Bu⁶, Jayne Stigler⁶ and Désirée van der Heijde⁷, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²AbbVie, Inc., Luzern, Switzerland, ³Toho University, Tokyo, Japan, ⁴University of Utah, Salt Lake City, UT, ⁵Great Lakes Clinical Trials, Chicago, IL, ⁶AbbVie, Inc., North Chicago, IL, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands
Background/Purpose: Upadacitinib (UPA), an oral Janus kinase inhibitor, has been evaluated in the treatment of AS both in patients (pts) naïve to biologic DMARDs (bDMARDs)1…
Abstract Number: 0384 • ACR Convergence 2021
A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio
Rouhin Sen¹, Emmeline Kim², Elizabeth Cheng³, Kavya Ganuthula⁴, Meika Fang⁵, Gail Kerr⁶, Jessica Walsh⁷, Elizabeth Chang⁸, Siba Raychaudhuri⁹, Andreas Reimold¹⁰ and Liron Caplan¹¹, ¹University of Colorado School of Medicine/Rocky Mountain Regional Veterans Affairs Medical Center (VAMC), Denver, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Rocky Mountain Regional VAMC, Aurora, CO, ⁴Rocky Mountain Regional VAMC/University of Colorado School of Medicine, Aurora, CO, ⁵David Geffen School of Medicine at UCLA/West Los Angeles Veterans Affairs Medical Center (VAMC), Los Angeles, CA, ⁶Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁷Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁸Phoenix Veterans Affairs Medical Center (VAMC), Phoenix, AZ, ⁹Sacramento Veterans Affairs Medical Center (VAMC)/University of California-Davis Health, Davis, CA, ¹⁰University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ¹¹Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Biomarkers of disease activity/severity and imaging outcomes in axial spondyloarthritis (axSpA) remain a challenge. The most common relevant biomarker is the C-Reactive Protein (CRP),…
Abstract Number: 0728 • ACR Convergence 2021
Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study
Philip Conaghan¹, Xavier Chevalier², Linda Mindeholm³, Ursula Schramm³, Jens Praestgaard³, Abdelkader Seroutou³, Ronenn Roubenoff³ and Matthias Schieker³, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Henri Mondor University Hospital and Paris University XII, UPEC, Créteil, France, Créteil, France, ³Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Knee osteoarthritis (OA) is a common musculoskeletal disease associated with pain and functional impairment. There are few effective therapies, often limited by side-effects.1 This…
Abstract Number: 0796 • ACR Convergence 2021
Validation of the Simplified Disease Activity Index (SDAI) with a Quick Quantitative C-reactive Protein Assay (SDAI-Q) in Patients with Rheumatoid Arthritis: A National, Multicenter Study
Julia Schally¹, Henning Christian Brandt², Jan Brandt-Jrgens³, Gerd Burmester⁴, Hildrun Haibel⁵, Henriette Käding¹, Kirsten Karberg⁶, Susanne Lüders⁷, Burkhard Muche¹, Mikhail Protopopov⁴, Valeria Rios Rodriguez⁴, Murat Torgutalp⁴, Maryna Verba⁸, Silke Zinke⁹, Denis Poddubnyy¹⁰ and Fabian Proft⁴, ¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ²Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, ³Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁶Praxis für Rheumatologie und Innere Medizin,, Berlin, Germany, ⁷Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ⁸Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁹Rheumapraxis Berlin, Berlin, Germany, ¹⁰Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Therapeutic decisions in RA patients should be based on regular disease activity assessment using scores like the Simplified Disease Activity Index (SDAI) or the…
Abstract Number: 0833 • ACR Convergence 2021
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study
Torsten Witte¹, Uta Kiltz², Florian Haas³, Elke Riechers⁴, Ulrich Prothmann⁵, Daniela Adolf⁶, Carsten Holland⁷, Rouven Hecht⁸, Alexander Rössler⁷, Kirsten Famulla⁸, Konrad Götz⁸ and Klaus Krüger⁹, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³Internistisch-Rheumatologische Facharztpraxis, Tübingen, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Knappschaftsklinikum Saar, Püttlingen, Germany, ⁶StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁹Rheumatological Practice Center, Munich, Germany
Background/Purpose: Upadacitinib (UPA) is a Janus kinase inhibitor that has been shown to be effective and well tolerated in patients with rheumatoid arthritis (RA) in…
Abstract Number: 0914 • ACR Convergence 2021
Response to Certolizumab Pegol in Patients with Non-Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Cut-Offs: Post-Hoc Analysis from a Phase 3 Multicenter Study
Philip Robinson¹, Stephen Hall², Bengt Hoepken³, Lars Bauer³, Eleni Demas⁴, Mindy Kim⁵ and Atul Deodhar⁶, ¹University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia, ²Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, ³UCB Pharma, Monheim am Rhein, Germany, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Smyrna, GA, ⁶Oregon Health & Science University, Portland, OR
Background/Purpose: Certolizumab pegol (CZP), an Fc-free, PEGylated tumor necrosis factor (TNF) inhibitor, has previously demonstrated efficacy and safety in patients with radiographic (r) and non-radiographic…
Abstract Number: 1196 • ACR Convergence 2021
Morning Stiffness Already Associates with Systemic Inflammation and Subclinical Joint Inflammation in the Pre-RA Phase of Arthralgia
Doortje Krijbolder¹, Fenne Wouters¹, Elise van Mulligen² and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Morning stiffness (MS) is characteristic for Rheumatoid Arthritis (RA) and associates with markers of systemic and local inflammation in RA-patients. In patients with arthralgia,…
Abstract Number: 1208 • ACR Convergence 2021
Composite Articular Index Including Acute Phase Reactants Should Not Be Used in Patients with Rheumatoid Arthritis Treated with Il6 Inhibitors but May Be Useful in Those Receiving Jak Inhibitors: Ultrasound Evidence
Andrés Ponce¹, Beatriz Frade-Sosa², Ramirez Julio³, Núria Sapena¹, Roberto Gumucio², Virginia Ruiz-Esquide², Rosa Morlà², Marta Bassas², Juan D Cañete⁴ and Jose A Gomez-Puerta², ¹Rheumatology Department, Hospital Clínic, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital Universitari Clinic, Barcelona, Spain, ⁴Rheumatology Department, Hospital Clinic, Barcelona, Spain
Background/Purpose: IL6 inhibitors (IL6i) have a dramatic effect on the reduction of C reactive protein (CRP) that does not always correlate with a significant improvement…
Abstract Number: 1401 • ACR Convergence 2021
Utility of CRP and ESR in the Assessment of Giant Cell Arteritis Relapse in a Phase 2 Trial of Mavrilimumab
Sebastian Unizony¹, Maria C. Cid², Daniel Blockmans³, Elisabeth Brouwer⁴, Lorenzo Dagna⁵, Bhaskar Dasgupta⁶, Bernhard Hellmich⁷, Eamonn Molloy⁸, Carlo Salvarani⁹, Bruce Trapnell¹⁰, Kenneth Warrington¹¹, Ian Wicks¹², Manoj Samant¹³, Teresa Zhou¹³, Lara Pupim¹³ and John F Paolini¹³, ¹Vasculitis and Glomerulonephritis Center, Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Vasculitis Research Group. Department of Autoimmune Diseases. Hospital Clínic. University of Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain, ³General Internal Medicine, UZ Leuven, Leuven, Belgium, ⁴University Medical Center Groningen, Groningen, Netherlands, ⁵Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University, Milan, Lombardia, Italy, ⁶Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁷Department of Internal Medicine, Rheumatology, and Immunology, Medius Kliniken, Kirchheim unter Teck, Germany, ⁸St Vincent's University Hospital, Dublin, Ireland, ⁹Unità Operativa di Reumatologia, Azienda USL-IRCCS di Reggio Emilia, Italy, Reggio Emilia, Italy, ¹⁰Translational Pulmonary Science Center, Cincinnati Children’s Hospital, Cincinnati, ¹¹Mayo Clinic, Rochester, Minnesota, ¹²Walter & Eliza Hall Institute & Melbourne Health, Melbourne, Australia, ¹³Kiniksa Pharmaceuticals Corp., Lexington, MA
Background/Purpose: Although giant cell arteritis (GCA) relapse is mostly defined by the recurrence of GCA signs/symptoms, in patients treated only with glucocorticoids, the C-reactive protein…
Abstract Number: 1795 • ACR Convergence 2021
Validation of the Disease Activity Index for Psoriatic Arthritis (DAPSA) with a Quick QuantitativeC-reactive Protein Assay (Q-DAPSA) in Patients with Psoriatic Arthritis (PsA): A Prospective,national, Multicenter Study
Fabian Proft¹, Julia Schally², Henning Christian Brandt³, Jan Brandt-Jrgens⁴, Gerd Burmester¹, Hildrun Haibel⁵, Henriette Käding², Kirsten Karberg⁶, Susanne Lüders⁷, Burkhard Muche², Mikhail Protopopov¹, Judith Rademacher¹, Valeria Rios Rodriguez¹, Murat Torgutalp¹, Maryna Verba⁸ and Silke Zinke⁹, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ³Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, ⁴Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁶Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ⁷Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ⁸Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁹Rheumapraxis Berlin, Berlin, Germany
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease with multiple musculoskeletal and dermatological manifestations. Due to this multifaceted clinical appearance, international guidelines do not provide…
Abstract Number: 1807 • ACR Convergence 2021
Relationships Between Fatigue and Hemoglobin/C-Reactive Protein Levels and Associations Between Fatigue and Clinical Response in Patients with Active Psoriatic Arthritis: Results from Two Randomized Controlled Trials of Guselkumab (TREMFYA®)
Proton Rahman¹, Philip Mease², Atul Deodhar³, Laure Gossec⁴, Arthur Kavanaugh⁵, Soumya Chakravarty⁶, Alexa Kollmeier⁷, Yan Liu⁸, Xiwu Lin⁸, May Shawi⁹ and Chenglong Han⁸, ¹Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ³Oregon Health & Science University, Portland, OR, ⁴Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ⁵University of California San Diego, La Jolla, CA, ⁶Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada
Background/Purpose: Fatigue is a key patient (pt)-reported symptom of psoriatic arthritis (PsA).1,2 Utilizing data from the Phase 3 DISCOVER-1 (D1) and -2 (D2) studies, these…
Abstract Number: 1920 • ACR Convergence 2021
Association of C-reactive Protein and Non-Steroidal Anti-inflammatory Drugs with Cardiovascular Events in Patients with Psoriatic Arthritis: A Time-dependent Cox Regression Analysis
Ho Man Lam¹, Ho So², Isaac Cheng¹, Edmund Li¹, Priscilla Wong³, Tena Li¹, Alex Lee¹ and Lai-Shan Tam⁴, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²CUHK, Hong Kong, China, ³Prince of Wales Hospital, Hong Kong, Hong Kong, ⁴Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)
Background/Purpose: Psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to underlying inflammation. Whether inflammatory burden and drugs used to suppress inflammation over time are…
Abstract Number: 0374 • ACR Convergence 2021
Validation of the Ankylosing Spondylitis Disease Activity Score with a Quick Quantitative Creactiveprotein Assay (ASDAS-qCRP) in Patients with Axial Spondyloarthritis (axSpA): Aprospective, National, Multicenter Study
Fabian Proft¹, Julia Schally², Henning Christian Brandt³, Jan Brandt-Jrgens⁴, Gerd Burmester¹, Hildrun Haibel⁵, Henriette Käding², Kirsten Karberg⁶, Susanne Lüders⁷, Burkhard Muche², Mikhail Protopopov¹, Judith Rademacher¹, Valeria Rios Rodriguez¹, Murat Torgutalp¹, Maryna Verba⁸, Silke Zinke⁹ and Denis Poddubnyy¹⁰, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ³Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, ⁴Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁶Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ⁷Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ⁸Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁹Rheumapraxis Berlin, Berlin, Germany, ¹⁰Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: According to international recommendations, the Ankylosing Spondylitis Disease Activity Score (ASDAS) is the preferred score for assessing disease activity in axial spondyloarthritis (axSpA) [1].…
Abstract Number: 0034 • ACR Convergence 2020
Gene Expression Signatures in C-Reactive Protein High and Low Rheumatoid Arthritis
Adam Cornish¹, Kristin Wipfler¹ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Transcriptome profiling has expanded our ability to identify biomarkers and therapeutic targets and better understand disease progression in a wide variety of conditions. Serum…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].